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ABSTRACT  
Introduction: Vitamin K antagonist (VKA) treatment requires routine monitoring using 
the international normalized ratio (INR). However, different INR assays may vary in 
their results. The aim of this study was to assess the agreement of three different INR 
methods, compared with thrombin generation, in patients on VKA treatment. 
Methods: Sixty patients attending the Anticoagulation Clinic at Mater Dei Hospital 
(Msida, Malta) for VKA monitoring between August-September 2015 were enrolled. 
The INR was tested using a point-of-care (POC) device (CoaguChek XS Plus, Roche 
Diagnostics) for both capillary and venous blood samples, a photo-optical (Sysmex CS-
2100i/CA-1500, Siemens) and a mechanical clot detection system (Thrombolyzer XRC, 
Behnk Elektronik). All assays used human recombinant thromboplastin as reagent. 
Thrombin generation was performed using the Calibrated Automated Thrombogram.  
Results: There was a negative curvilinear correlation between the Endogenous 
Thrombin Potential and different INR assays (r  -0.75) and a strong positive linear 
correlation between the CoaguChek XS Plus on capillary samples and the other INR 
methodologies (r  0.96). 
Conclusion: All different INR assays showed good correlation with the thrombin 
generation potential. The POC INR showed one of the highest correlation coefficients 
with thrombin generation, confirming the POC devices as an accurate, valid alternative 
to laboratory INR in VKA patients. 
 
Keywords: Accuracy, Warfarin, International Normalized Ratio, Point-of-Care 
Systems, Thrombin Generation 
  
4 
 
INTRODUCTION 
Vitamin K antagonists (VKAs) have a narrow therapeutic window, several food and 
drug interactions and a variable anticoagulant response, which explain the need for 
periodical anticoagulation monitoring and dose adjustment (1). Since VKAs inhibit the 
synthesis of vitamin K-dependent coagulation factors (factors II, VII, IX and X), they 
are monitored using laboratory tests that assess the extrinsic pathway of the coagulation 
cascade. The prothrombin time (PT) measures the time to clot formation of citrated 
plasma, after recalcification and addition of thromboplastin to trigger coagulation, and 
is usually expressed as international normalized ratio (INR). The WHO recommended 
method for PT testing in relation to VKA therapy is the manual tilt-tube technique (2), 
but currently most PT determinations are performed using automated coagulation 
analysers, such as photo-optical or electro-mechanical coagulometers. Furthermore, in 
the last two decades several portable coagulometers, also known as point-of-care (POC) 
devices, have been developed for the self-care of patients prescribed with VKAs (3). 
More recently, we saw the advent of  global coagulation assays, such as thrombin 
generation, which may have the potential to better evaluate all phases of coagulation 
(4). 
Several studies indicated an excellent correlation between photo-optical and electro-
mechanical coagulation analysers (5, 6), while the comparison between POC and 
laboratory or manual INRs showed a certain variability in the results, with  potential 
clinical disagreement and differences in VKA dosing (7-10). However, it is not known 
which test actually correlates better with the overall blood coagulation potential, since 
these three INR methods have never been compared simultaneously with global 
coagulation assays. 
5 
 
The aim of this study was to assess the agreement of three different INR assays, 
compared with thrombin generation, in patients on VKA treatment. 
 
MATERIAL AND METHODS 
Study population 
Consecutive adult patients attending the Anticoagulation Clinic at Mater Dei Hospital 
(in Msida, Malta) for warfarin monitoring were screened. We included 30 patients 
deemed eligible for POC monitoring according to the local protocol (target INR 
and at least 3 consecutive INRs within the therapeutic range, absence of 
antiphospholipid syndrome, liver disease, severe renal failure, active cancer, or dual 
antiplatelet therapy) and 30 random patients, in order to cover a broader range of INR 
values. Patients were recruited during the months of August and September 2015.  
The study was reviewed and approved by the University of Malta Research and Ethics 
Committee and written informed consent was obtained from all patients before 
inclusion.  
 
Sample collection and tests performed 
Laboratory INR 
From each patient, one venous blood sample was collected using a 10 mL syringe and a 
21G needle, in order to fill in 3 coagulation tubes, each containing 2 mL of whole blood 
and sodium citrate 0.109M/3.2% (Vacuette, Greiner Bio-One). One tube was processed 
according to the standard system at Mater Dei Hospital at the time of this study. This 
tube was centrifuged for 10 minutes at 2500 g and plasma was analysed using a photo-
optical clot detection system (Sysmex CS-2100i or CA-1500, Siemens Healthcare 
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Diagnostics) and human recombinant thromboplastin (Dade Innovin Reagent, Siemens 
Healthcare Diagnostics). We had previously tested with both Sysmex analysers 33 
samples with various INRs, ranging from 0.9 to 4.45, and found no statistical difference 
in the PT and the INR between the two analysers (data not shown). 
The two remaining tubes underwent double centrifugation (2500 g for 10 min twice) 
with plasma separation, in order to obtain platelet poor plasma (PPP) within a 2 hour 
time frame from phlebotomy. They were stored in 300 µL aliquots at -80° C. It has 
previously been demonstrated that freezing plasma does not affect INR testing (11).  
Afterwards, one scientist tested the INR on thawed PPP using a mechanical clot 
detection system (Thrombolyzer XRC, Behnk Elektronik) and the same human 
recombinant thromboplastin (Dade Innovin Reagent, Siemens Healthcare Diagnostics). 
The INR is calculated dividing tKHSDWLHQW¶V37E\WKHPHDQRIWKH37s of adult normal 
subjects, to WKHSRZHURIWKHWKURPERSODVWLQ¶V,QWHUQDWLRQDO6HQVLWLYLW\,QGH[,6,(12), 
according to the following formula: 
 
INR calibration was performed locally, on each analyser, using a calibrator kit (PT-
Multi Calibrator, Siemens) composed of five lyophilized calibration plasmas.  
 
Point-of-care testing 
All 60 patients were tested using the CoaguChek XS Plus (Roche Diagnostics) 
coagulometer. Quality control (QC) analysis for POC was performed at the beginning of 
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each testing day. One researcher performed all the tests. Both capillary and venous 
blood samples were tested with the CoaguChek XS Plus. Capillary blood samples were 
obtained by finger prick and applied on a test strip within 10 seconds. Non-citrated 
venous blood samples were obtained from the syringe used to draw the venous blood, 
after filling the coagulation tubes and after discharging few blood drops. The same 
CoaguChek XS Plus coagulometer was used throughout study. Two lots of test strips 
were used during the study (233 430-11 and 202 053-11). As per manufacturer 
instructions, the CoaguChek XS Plus system utilizes human recombinant 
thromboplastin with ISI=1.0 (13). 
 
Thrombin generation 
Frozen aliquots were shipped to the Coagulation Laboratory at the Royal Hallamshire 
Hospital (in Sheffield, United Kingdom) in dry-ice. Thrombin generation was 
performed using the Calibrated Automated Thrombogram (CAT), according to the 
method described by Hemker et al (14).  
Prior to this analysis, samples were thawed in a water bath at 37° C for 5 minutes. 
Afterwards, 80 µL of PPP were added to 20 µL of tissue factor trigger at a 
concentration of 5pM (PPP-reagent, Thrombinoscope BV, Maastricht, the Netherlands) 
in a 96-well plate. All samples were tested in duplicate and one calibrator (Thrombin 
Calibrator, activity 580 nM) well was run in parallel. Three QC plasma samples were 
tested in each run. 
The reaction was initiated after automated dispensing of 20 µL of fluorogenic substrate 
(FluCa-kit, Thrombinoscope BV, Maastricht, the Netherlands). The fluorescence 
intensity was measured for 1 hour using a Fluoroskan Ascent fluorimeter (Thermo 
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Electron Corporation), after the samples were incubated for 10 min at 37ºC. Using a 
dedicated software (Thrombinoscope BV, Maastricht, the Netherlands, version 
3.4.0.154), the following parameters were calculated: lag time (LT), peak thrombin 
concentration (Peak), time to peak thrombin (ttPeak), endogenous thrombin potential 
(ETP) and velocity index.  
 
Statistical analysis 
We collected information regarding demographic characteristics of the population, past 
medical history, details of the warfarin treatment and concomitant medications.  
Continuous variables were expressed as mean with standard deviation (SD) or median 
with interquartile range (IQR); categorical variables were expressed as counts and 
percentages. Continuous variables were compared using WKH 6WXGHQW¶V W-test or the 
Mann-Whitney U test; categorical variables were compared using the Chi square or 
Fisher's exact tests, as appropriate. The correlation between different laboratory tests 
was evaluated using the non-SDUDPHWULF6SHDUPDQ¶VUDQNFRUUHODWLRQWHVWDFFRUGLQJWR
data distribution, and the correlation coefficients (r) were calculated. The mean INRs 
obtained with different methodologies were compared using one-way repeated measures 
$129$ZLWK%RQIHUURQL¶VSRVW-hoc correction. 
The statistical agreement between different INR methodologies was evaluated creating 
Bland-Altman plots (or difference plots) with the mean of the two measurements on the 
x-axis and the difference between the two values on the y-axis (15). The estimated mean 
bias is the mean difference between the two values and the 95% limits of agreement are 
computed as mean bias ± 1.96 SD (15).  
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In order to evaluate the clinical agreement and to estimate the percentage of INR values 
which might have resulted in a different clinical management, the INR values were 
categorized as above, within or below the INR therapeutic range (2.0-3.0 for patients 
with atrial fibrillation, venous thromboembolism and aortic valve replacement; and 2.5-
3.5 for patients with mitral valve replacement).  
Data analysis was performed using the statistical software STATA SE 12 (StataCorp 
LP, College Station, TX, USA). Two-tailed p values less than 0.05 were considered 
statistically significant. 
 
RESULTS 
Study population 
Sixty patients were enrolled in this study. Mean (SD) age was 68.5 (11.5) years and 26 
(43.3%) were males. The most common indications for warfarin treatment were atrial 
fibrillation (63.3%) and venous thromboembolism (26.7%), followed by mechanical 
heart valve replacement (8.4%). The majority of patients (73.3%) were on oral 
anticoagulant treatment for more than a year. The current median (IQR) dose of 
warfarin was 4 (3-5) mg. Comorbidities and concomitant medications in our population 
are summarized in Table 1. None of these patients had known antiphospholipid 
syndrome. 
 
Different INR methodologies 
Using the standard laboratory instrumentation in our Coagulation Laboratory (the 
Sysmex CS-2100i/CA-1500), mean (± SD) INR was 2.46 (± 0.75), with a range from 
1.37 to 4.92. Mean and median INR values measured with the other methodologies 
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were slightly higher and are summarized in Table 2. Mean INR obtained using the 
Sysmex CS-2100i/CA-1500 analysers was significantly different from the CoaguChek 
XS Plus on capillary and venous samples and from the Thrombolyzer XRC results (p 
values < 0.001). 
 
Thrombin generation 
The intra-assay coefficient of variation (CV) of thrombin generation was 4.3%. The 
inter-assay CV was 13.7% for the normal QC and 6.8% for the warfarin QC. 
Thrombin generation results are summarized in Table 3. Patients with VTE had a 
slightly lower lag time and time to peak compared to patients with atrial fibrillation 
(AF), although this was not statistically significant (p=0.08 and p=0.06, respectively). 
This result was not explained by other variables that were comparable in the two groups 
(e.g. median INR 2.35 in AF patients vs. 2.3 in VTE patients, p=0.99; median age 69.5 
vs. 67 years, p=0.54; warfarin treatment duration more than 1 year 71.7% vs. 73.3%, 
p=1.00; median TTR in the previous 3 months 67.8% vs. 67.0%, p=0.77, respectively). 
There was no difference in the other parameters of the thrombin generation curve, as 
reported in Table 3. 
 
Correlation between thrombin generation and different INR methodologies 
There was a negative curvilinear correlation between the ETP and the INR measured 
with the Sysmex CS-2100i/CA-1500 (r = -0.75, p<0.001), the CoaguChek XS Plus on 
capillary (r = -0.80, p<0.001) and venous blood (r = -0.78, p<0.001), and the 
Thrombolyzer XRC (r = -0.78, p<0.001), as shown in Figure 1. 
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Comparison between INRs  
A strong positive linear correlation was found between the CoaguChek XS Plus, tested 
RQ FDSLOODU\ VDPSOHV DQG WKH RWKHU ,15 PHWKRGRORJLHV VKRZLQJ 6SHDUPDQ¶V U
coefficients above 0.95 (Table 4 and Figure 2). The CoaguChek XS Plus tended to 
overestimate the INR by a mean of approximately 0.3 INR units, compared to the 
Sysmex CS-2100i/CA-1500. The agreement, represented by the Bland-Altman or 
difference plots, is reported in Figure 3.  
From a clinical perspective, the INR values within the same clinical category, compared 
to the CoaguChek XS Plus on capillary samples, were 93.3% for the CoaguChek XS 
Plus on venous samples; 78.3% for the Sysmex CS-2100i/CA-1500; and 93.2% for the 
Thrombolyzer XRC. However, the disagreement between the two methods would never 
lead to antagonistic behaviour (such as dose increase vs. dose reduction or viceversa).  
 
DISCUSSION 
To the best of our knowledge, this is the first time that three different INR assays 
(namely the CoaguChek XS Plus, the Sysmex CS-2100i/CA-1500 and the 
Thrombolyzer XRC) have been simultaneously compared with the thrombin generation 
assay. All the INR assays used human recombinant thromboplastin as reagent, therefore 
the difference in results was mainly due to the different analysers. 
We found a negative curvilinear relationship between the ETP measured by the CAT 
and the INR values, with 6SHDUPDQ¶Vcoefficients ranging between -0.80 and -0.75. A 
similar negative correlation was already reported by Gatt et al. in comparison with the 
Sysmex CA-1500 (16). In our study thrombin generation showed a better correlation 
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with the CoaguChek XS Plus and the Thrombolyzer XRC, than with the Sysmex CS-
2100i/CA-1500. 
We also found a strong positive linear correlation between the CoaguChek XS Plus, 
tested on capillary samples, and the other INR methodologies, with all 6SHDUPDQ¶V
coefficients above 0.95. The correlation was almost perfect for the CoaguChek XS Plus 
tested on capillary samples vs. venous samples with a mean (± SD) bias of 0.002 (± 
0.11) INR units, suggesting that this pre-analytical variable does not interfere with the 
INR values, if the test is correctly performed. Similar results were obtained by Plesch et 
al. who found a mean bias of less than ± 0.02 INR units between the capillary and 
venous sample, albeit using a different device, the CoaguChek XS (17). In our study, 
the correlation was also very strong when the CoaguChek XS Plus was compared with 
the photo-optical (Sysmex CS-2100i/CA-1500) and the mechanical clot detection 
methods (Thrombolyzer XRC). Previous studies, that compared the CoaguChek XS 
Plus with photo-optical (Sysmex analysers) or mechanical clot detection methods 
(STAGO analysers), found correlation coefficients approximately 0.95-0.96 (8, 18, 19); 
however, the CoaguChek XS Plus had never been compared before with different 
laboratory techniques simultaneously. 
Although the statistical agreement was very good, clinical disagreement between the 
CoaguChek XS Plus on capillary samples and the other INR assays ranged from 6.7% 
to 21.7% of patients, resulting in possibly different, but never antagonistic, warfarin 
management. A previously published study reported clinical disagreement in 26-29% of 
cases, but the management differed only by minor interventions (9). Furthermore, 
considering that VKA patients managed with a POC device should be monitored in this 
way for a certain period of time, without continuously switching between POC and 
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laboratory INR, this small difference is unlikely to negatively interfere with the clinical 
management of VKA patients. 
Our findings have important implications in the international literature. Despite the 
recent discovery of the novel direct oral anticoagulants, VKAs will remain the treatment 
of choice for several categories of patients, such as those with valvular AF, mechanical 
heart valves or with severe renal insufficiency. Portable coagulometers, compared to 
traditional laboratory INR, are less invasive and can provide immediate results. 
Furthermore, POC can allow a more practical INR monitoring, since they can be used in 
different settings outside the hospital and they can also allow patient self-testing and 
self-management. Portable coagulometers therefore represent an alternative to standard 
laboratory INR and our results can provide reassurance on the accuracy of the 
CoaguChek XS Plus device. 
The strengths of our study include the simultaneous comparison of thrombin generation 
measured by the CAT with three different INR assays, all using the same 
thromboplastin in order to reduce possible variability due to this analytical variable. 
Furthermore, we decided to reduce variability by asking a single investigator to perform 
all the POC tests. However, there are also some limitations that need to be 
acknowledged. First, the small number of patients, although similar to previous studies 
(17, 18), resulted in a small number of INRs above 4.0, thus precluding the possibility 
of a sensitivity analysis in this patient subgroup. Second, despite the potential to better 
assess all phases of coagulation, thrombin generation is not yet considered a validated 
test for monitoring anticoagulation. However, we chose to compare different INR 
methodologies with thrombin generation because the latter is known to show more 
variation in VKA patients and has the potential to better identify small differences in 
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test accuracy, than simply comparing different INR methodologies among each other. 
Third, all POC measurements were performed by a trained scientist, and our results 
might not generalizable, for example, to all patients performing INR self-testing.  
In conclusion, our study showed that the relationship between INR results and thrombin 
generation does not differ depending on the assay used for INR measurement. Despite 
not being generally FRQVLGHUHGDVWKHµJROGVWDQGDUG¶WKH32&,15VKRZHGRQHRIWKH
highest correlation coefficients with thrombin generation, therefore confirming the POC 
devices as an accurate and valid alternative to laboratory INR in VKA patients. 
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Table 3.  Results of thrombin generation test in the overall population and in the 
comparison between patients with venous thromboembolism and atrial 
fibrillation 
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Figure 1.  Correlation between the Endogenous Thrombin Potential (ETP) and the 
INR, measured with the Sysmex CS-2100i/CA-1500 (a), the Thrombolyzer 
XRC (b), the CoaguChek XS Plus on capillary samples (c) and on venous 
samples (d) 
Figure 2. Correlation between the INR measured with the CoaguChek XS Plus on 
capillary samples and the CoaguChek XS Plus on venous samples (a), the 
Sysmex CS-2100i/CA-1500 (b), and the Thrombolyzer XRC (c)  
Figure 3.  Bland Altman plots representing the difference between the CoaguChek XS 
Plus on capillary samples and the Sysmex CS-2100i/CA-1500 
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Table 1. Baseline characteristics of the population 
 N. of patients = 60 
Age (years), mean (SD) 68.5 (11.5) 
Male sex, n (%) 26 (43.3%) 
 
Indication for anticoagulant treatment: 
x Atrial fibrillation, n (%) 38 (63.3%) 
x Venous thromboembolism, n (%)  16 (26.7%) 
x Aortic valve replacement, n (%) 4 (6.7%) 
x Mitral valve replacement, n (%) 1 (1.7%) 
x Cerebrovascular accident, n (%) 1 (1.7%) 
Duration of the anticoagulant treatment: 
x PRQWKVQ 6 (10.0%) 
x 3-6 months, n (%) 6 (10.0%) 
x 6-12 months, n (%) 4 (6.7%) 
x > 1 year, n (%) 44 (73.3%) 
Current warfarin dose (mg), median (IQR) 4 (3-5) 
 
Comorbidities:  
- Hypertension, n (%) 49 (81.7%) 
- Diabetes mellitus, n (%) 22 (36.7%) 
- Dyslipidemia, n (%) 32 (53.3%) 
- Coronary artery disease, n (%) 18 (30.0%) 
- Hypothyroidism, n (%) 8 (13.3%) 
- Previous stroke, n (%) 3 (5.0%) 
- Chronic obstructive pulmonary disease, n (%) 5 (8.3%) 
- Malignancy, n (%)  8 (13.3%) 
- Smokers: current, n (%) / previous, n (%) 5 (8.3%) / 13 (21.7%) 
- Obesity, n (%) 29 (48.3%) 
 
Concomitant medications: 
- Antiplatelet*, n (%) 5 (8.3%) 
- Steroids, n (%) 1 (1.7%) 
- Statins, n (%) 35 (58.3%) 
- ACE-inhibitors or ARBs, n (%) 42 (70.0%) 
- Diuretics, n (%) 34 (56.7%) 
- Beta-blockers, n (%) 22 (36.7%) 
- Calcium channel blockers, n (%) 11 (18.3%) 
- Digoxin, n (%) 14 (23.3%) 
- Levothyroxine, n (%) 8 (13.3%) 
- Proton pump inhibitors, n (%) 10 (16.7%) 
- Metformin, n (%) 17 (28.3%) 
17 
 
Legend:  ACE = angiotensin-converting-enzyme; ARB = angiotensin II receptor blockers; IQR = 
interquartile range; SD = standard deviation 
* Antiplatelet therapy refers to aspirin or clopidogrel, none of the patients was receiving dual antiplatelet 
therapy. 
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Table 2. Summary of INR measurements using different methodologies  
Instrument (n of tests) Mean INR (SD) Median INR (IQR) INR range 
Sysmex CS-2100i/CA-1500 
(60) 2.46 (0.75) 2.31 (1.95-2.74) 1.37-4.92 
CoaguChek XS Plus 
(capillary blood) 
(60) 
2.74 (0.86) 2.6 (2.2-3.1) 1.4-5.8 
CoaguChek XS Plus 
(venous blood) 
(60) 
2.74 (0.82) 2.6 (2.2-3.0) 1.4-5.7 
Thrombolyzer XRC  
(59*) 2.71 (0.85) 2.52 (2.14-2.97) 1.34-5.33 
Legend:  INR = international normalized ratio; IQR = interquartile range; SD = standard deviation 
*Thrombolyzer results were available for 59 patients, since one patient had a difficult blood sampling and 
only a limited amount of plasma was available. 
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Table 3. Results of thrombin generation test in the overall population and in the 
comparison between patients with venous thromboembolism and atrial fibrillation 
 
Overall population * 
 
Parameter Mean (SD) Median (IQR) Range 
Lag time (min) 6.35  (1.99) 
6  
(5.17-7.17) 3.47-13 
Peak thrombin concentration 
(nM) 
101.66  
(44.51)   
91.49  
(72.51-121.2) 29.99-269.37 
Time to peak (min) 9.23 (2.15)  
8.83  
(7.67-10.17) 5.97-16 
Endogenous thrombin 
potential (nM/min) 
596.75  
(265.26)   
547.5  
(419-722.5)  186.5-1835 
Velocity index (nM/min) 36.53  (17.76)  
31.34  
(25.22-47.91) 8.59-85.19 
 
 
Comparison between patients with atrial fibrillation and venous thromboembolism ** 
 
Parameter AF patients (n = 38) 
VTE patients 
(n = 15) p value 
Lag time (min) 6.33  (5.33-7.67) 
5.17  
(4.8-6.33) 0.08 
Peak thrombin concentration 
(nM) 
83.82  
(69.05-121.2) 
97.57  
(77.37-135.39) 0.43 
Time to peak (min) 9.33  (8-10.65) 
7.83  
(7.67-9) 0.06 
Endogenous thrombin 
potential (nM/min) 
508.5  
(398-722.5) 
547.5  
(465-803) 0.40 
Velocity index (nM/min) 30.6  (24.02-42.72) 
38.45  
(25.45-47.98) 0.44 
* Thrombin generation results were available for 59 patients, since the thrombin generation curve was not 
computable in one patient with VTE 
** All parameters are reported as median (IQR)  
20 
 
Legend:  AF = atrial fibrillation; IQR = interquartile range; SD = standard deviation; VTE = venous 
thromboembolism  
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Table 4. Agreement of the CoaguChek XS Plus on capillary blood samples, with 
the other INR methodologies 
Comparison 
6SHDUPDQ¶V
correlation 
coefficient r  
(p value) 
INR difference, 
mean (± SD) 
Magnitude of absolute 
difference, n (%) 
< 0.5 0.5-1.0 > 1.0 
CoaguChek XS Plus  
(capillary blood)  
vs. 
CoaguChek XS Plus  
(venous blood)  
0.9856 
(< 0.001) 0.002 (0.11) 
60 
(100%) 0 0 
CoaguChek XS Plus  
(capillary blood)  
vs.  
Sysmex CS-2100i/CA-1500 
0.9699 
(< 0.001) 0.28 (0.18) 
53 
(88.3%) 
7 
(11.7%) 0 
CoaguChek XS Plus  
(capillary blood)  
vs.  
Thrombolyzer XRC  
0.9646 
(< 0.001) 0.04 (0.18) 
58 
(98.3%) 
1 
(1.7%) 0 
Legend:  INR = international normalized ratio; SD = standard deviation 
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Figure 1. Correlation between the Endogenous Thrombin Potential (ETP) and the INR, measured with the Sysmex CS-2100i/CA-
1500 (a), the Thrombolyzer XRC (b), the CoaguChek XS Plus on capillary samples (c) and on venous samples (d) 
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Figure 2. Correlation between the INR measured with the CoaguChek XS Plus on capillary samples and the CoaguChek XS Plus 
on venous samples (a), the Sysmex CS-2100i/CA-1500 (b), and the Thrombolyzer XRC (c)  
The dashed line represents the perfect correlation, while the continuous line is the actual correlation between the two different INR methodologies 
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Figure 3. Bland Altman plots representing the difference between the CoaguChek 
XS Plus on capillary samples and the Sysmex CS-2100i/CA-1500 
The dashed line represents the mean difference, while the grey area defines the 95% limits of 
agreement 
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